Allarity Therapeutics, Inc.
ALLR
$1.61
-$0.15-8.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.66% | -21.11% | 142.46% | -35.88% | -24.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 0.25% | -- | -- |
| Total Operating Expenses | 22.60% | -28.40% | 49.97% | -41.03% | -18.89% |
| Operating Income | -22.60% | 28.40% | -49.97% | 41.03% | 18.89% |
| Income Before Tax | -42.42% | 28.98% | -354.73% | -169.10% | 31.55% |
| Income Tax Expenses | -- | -- | -100.00% | -- | -- |
| Earnings from Continuing Operations | -42.42% | 28.91% | -332.81% | -160.63% | 31.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.42% | 28.91% | -332.81% | -160.63% | 31.55% |
| EBIT | -22.60% | 28.40% | -49.97% | 41.03% | 18.89% |
| EBITDA | -22.28% | 28.62% | -50.23% | 41.02% | 18.74% |
| EPS Basic | 95.53% | -- | -- | -- | -- |
| Normalized Basic EPS | 95.42% | -- | -- | -- | -- |
| EPS Diluted | 95.53% | -- | -- | -- | -- |
| Normalized Diluted EPS | 95.42% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 3,013.02% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 3,013.02% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |